referred as pulmonary arterial hypertension (PAH). Pulmonary arterial hypertension can also be associated with autoimmune diseases; drug use such as methamphetamines or diet drugs; human immunodeficiency virus (HIV); liver disease and congenital heart disease.
Pulmonary hypertension is commonly associated with a variety of lung conditions with low oxygen levels. These include COPD, emphysema, interstitial lung disease, chronic pulmonary blood clots or sleep apnea. When pulmonary hypertension arises from cardiac conditions such as heart failure or heart valve disease, it is referred to as a pulmonary venous hypertension. However, it is important to remember that pulmonary hypertension can be associated with multiple causes.
What are symptoms of pulmonary hypertension?
Healthy pulmonary arteries of the lungs are elastic. They expand and contract with each beat of the heart. In pulmonary hypertension, arteries stiffen and thicken. This leads to increased resistance to blood passing through the vessel, thereby increasing pressure. Higher pulmonary pressure can lead to symptoms of pulmonary hypertension. These symptoms of pulmonary hypertension usually involve the heart. Common symptoms may include:  Shortness of breath, especially with exertion  Low oxygen levels  Chest pain or pressure  Near-fainting/fainting  Fatigue  Palpitations  Swelling of the ankles or abdomen  Heart failure (in advanced cases)
How is pulmonary hypertension diagnosed?
The diagnosis of pulmonary hypertension can be difficult and is often delayed until the disease has progressed. Pulmonary hypertension cannot be diagnosed non-invasively. When diagnosing pulmonary hypertension, an ultrasound of the heart, or echocardiogram, can provide an estimate of the pressure in the heart.
Only a procedure called a right heart catheterization (RHC) can directly measure blood pressure in the lungs and determine if pulmonary hypertension is present. A right heart catheterization can also be used to determine if pulmonary hypertension is responsive to intravenous vasodilator medication. This will help determine whether or not a person is a candidate for chronic medication treatment.
Other tests are performed to screen for associated diseases, including blood tests, EKG, chest X-ray, pulmonary function testing, and a test for lung blood clots called a ventilation/perfusion scan (VQ scan). A 6-minute walk time is typically performed to assess a person's exercise capacity and need to oxygen therapy.
How is pulmonary hypertension treated?
Treatment of pulmonary hypertension is directed toward improving symptoms, improving exercise capacity and delaying progression of the disease. The treatment used for pulmonary hypertension depends upon its underlying cause. Pulmonary hypertension can improve with treatment of associated heart or lung disease.
Non-medication Treatments
Important non-medication treatment includes:  Oxygen therapy  Quitting smoking  Removal of deleterious drugs  Routine exercise (with the guidance of your pulmonary hypertension doctor)
Medication and other Treatments
People whose pulmonary blood pressure "responds" to intravenous vasodilator treatment during right heart catheterization may be candidates for calcium channel blocker therapy. People with idiopathic pulmonary arterial hypertension that does not respond to vasodilator challenge during right heart catheterization or who do not improve with calcium channel blocker treatment, or people who have inherited, or connective tissue-associated pulmonary hypertension are candidates for oral medications. These oral medications include:  Phosphodiesterase-5 (PDE-5) inhibitors (sildenafil or tadalafil),  Soluble guanylate cyclase stimulator (riociguat),  Endothelin receptor antagonists (ERAs) (bosentan, ambrisentan, macitentan). PDE-5 inhibitors and ERAs can improve exercise capacity, and sometimes, slow the progression of the disease. It is unclear if these medication provide benefit to people who have pulmonary hypertension associated with lung or heart disease.
Prostanoid Medications
Medications called prostanoids may improve symptoms and, sometimes, survival. Prostanoids can be given by inhalation (treprostinil), subcutaneous injection (treprostinil) or via IV infusion (epoprostenol, treprostinil). There are also oral medications as well (selexipag, treprostinil). While the prostanoids can provide significant improvement, they have many side effects. They should be managed at pulmonary hypertension centers experienced with their use.
In people who have chronic thromboembolic pulmonary hypertension (CTEPH), surgical removal of blood clots or balloon pulmonary artery angioplasty is always considered, as this can be of greatest benefit.
When pulmonary hypertension develops into heart failure, diuretics, digitalis and sodium restriction can be helpful. In people who have pulmonary hypertension due to chronic blood clots, treating with a blood thinner is very important to prevent more blood clots. Finally, lung or combined heart/lung transplantation may be appropriate in people who have progressive disease and have failed traditional therapy.
What do we do at National Jewish Health?
We provide comprehensive cardiology evaluation and consultation and non-invasive cardiac testing. We evaluate and treat heart problems such as coronary artery disease, high blood pressure, high cholesterol, heart valve problems and heart failure. In addition to traditional heart problems, we offer expertise in many other focus areas, including evaluation of patients with shortness of breath with exercise, sarcoid of the heart, diastolic dysfunction and secondary pulmonary hypertension.
Why National Jewish Health?
At National Jewish Health, we treat the whole person, not just the disease. Our cardiology team works with healthcare providers from all areas of the medical center, including rehabilitation therapists, dietitians and clinical researchers.
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